Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Stage III Unresectable Non-small Cell Lung Cancer Following Primary Chemoradiotherapy

NCT00960115 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT00960115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00960115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Stage III Unresectable Non-small Cell Lung Cancer Following Primary Chemoradiotherapy
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2008
Completion date
June 30, 2015
Enrollment
178 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer